Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Telesis Bio (TBIO) Competitors

Telesis Bio logo
$0.0010 0.00 (0.00%)
As of 05/15/2026 12:19 PM Eastern
Compare

TBIO vs. THMO, HTGMQ, OLITW, PRENW, and QSIAW

Should you buy Telesis Bio stock or one of its competitors? MarketBeat compares Telesis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telesis Bio include ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), and Quantum-Si (QSIAW). These companies are all part of the "measuring and control equipment" industry.

How does Telesis Bio compare to ThermoGenesis?

ThermoGenesis (NASDAQ:THMO) and Telesis Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

ThermoGenesis has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

ThermoGenesis has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

In the previous week, Telesis Bio had 1 more articles in the media than ThermoGenesis. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for ThermoGenesis. ThermoGenesis' average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Telesis Bio Neutral

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ThermoGenesis has higher earnings, but lower revenue than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

Summary

ThermoGenesis beats Telesis Bio on 7 of the 11 factors compared between the two stocks.

How does Telesis Bio compare to HTG Molecular Diagnostics?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Telesis Bio (NASDAQ:TBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

37.6% of Telesis Bio shares are owned by institutional investors. 2.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HTG Molecular Diagnostics has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

In the previous week, Telesis Bio had 1 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for HTG Molecular Diagnostics. HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
Telesis Bio Neutral

HTG Molecular Diagnostics has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market.

HTG Molecular Diagnostics has higher earnings, but lower revenue than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

Summary

HTG Molecular Diagnostics and Telesis Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Telesis Bio compare to OmniLit Acquisition?

OmniLit Acquisition (NASDAQ:OLITW) and Telesis Bio (NASDAQ:TBIO) are both measuring and control equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Telesis Bio had 1 more articles in the media than OmniLit Acquisition. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for OmniLit Acquisition. OmniLit Acquisition's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
OmniLit Acquisition Neutral
Telesis Bio Neutral

OmniLit Acquisition has higher earnings, but lower revenue than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmniLit AcquisitionN/AN/AN/AN/AN/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

37.6% of Telesis Bio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

OmniLit Acquisition has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
OmniLit AcquisitionN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

Summary

Telesis Bio beats OmniLit Acquisition on 4 of the 6 factors compared between the two stocks.

How does Telesis Bio compare to Prenetics Global?

Telesis Bio (NASDAQ:TBIO) and Prenetics Global (NASDAQ:PRENW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Telesis Bio had 1 more articles in the media than Prenetics Global. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 1.89 beat Telesis Bio's score of 0.00 indicating that Prenetics Global is being referred to more favorably in the news media.

Company Overall Sentiment
Telesis Bio Neutral
Prenetics Global Very Positive

Prenetics Global has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
Prenetics Global N/A N/A N/A

37.6% of Telesis Bio shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prenetics Global has lower revenue, but higher earnings than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
Prenetics Global$92.39MN/AN/AN/AN/A

Summary

Telesis Bio beats Prenetics Global on 4 of the 7 factors compared between the two stocks.

How does Telesis Bio compare to Quantum-Si?

Telesis Bio (NASDAQ:TBIO) and Quantum-Si (NASDAQ:QSIAW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

37.6% of Telesis Bio shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Telesis Bio had 1 more articles in the media than Quantum-Si. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 1.87 beat Telesis Bio's score of 0.00 indicating that Quantum-Si is being referred to more favorably in the news media.

Company Overall Sentiment
Telesis Bio Neutral
Quantum-Si Very Positive

Quantum-Si has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
Quantum-Si N/A N/A N/A

Quantum-Si has lower revenue, but higher earnings than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
Quantum-Si$1.85MN/AN/AN/AN/A

Summary

Telesis Bio beats Quantum-Si on 4 of the 7 factors compared between the two stocks.

Get Telesis Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TBIO vs. The Competition

Export
MetricTelesis BioAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$2K$2K$6.25B$12.29B
Dividend YieldN/AN/A2.80%5.30%
P/E Ratio0.00N/A20.8625.23
Price / Sales0.000.00550.9175.54
Price / CashN/AN/A27.4837.30
Price / Book0.010.019.676.63
Net Income-$47.72M-$47.72M$3.56B$335.59M
7 Day PerformanceN/AN/A-1.69%-1.20%
1 Month PerformanceN/AN/A-2.65%-1.16%
1 Year PerformanceN/AN/A30.03%28.10%

Telesis Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBIO
Telesis Bio
N/A$0.00
flat		N/A-91.3%$2K$225.09MN/A200
THMO
ThermoGenesis
N/AN/AN/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
OLITW
OmniLit Acquisition
N/A$1.20
+5.3%		N/A+2,240.9%$0.00N/AN/A3
PRENW
Prenetics Global
N/A$0.02
+0.6%		N/AN/A$0.00$92.39MN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TBIO) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel